Please log in, or sign up for a new account and purchase a subscription to continue reading.
Please log in, or sign up for a new account and purchase a subscription to continue reading.
Please purchase a subscription to continue reading.
Your current subscription does not provide access to this content.
Sorry, no promotional deals were found matching that code.
Promotional Rates were found for your code.
Sorry, an error occurred.
do not remove
Harrow Inc. stocks will seek to rebound Tuesday after a Monday nosedive that came as the company released a first quarter report that missed analyst estimates for earnings per share and revenue.
At the conclusion of the trading session, shares of the Nashville-based eye care pharmaceutical company (ticker: HROW) were priced at $29.03, down 23.7 percent (the equivalent decrease of $9.01 per share) on heavy volume, according to Yahoo Finance. About 5.39 million shares traded compared to a daily average of about 725,100.
According to a company release, Harrow recorded about $44.2 million in Q1 revenue, down from the $47.83 million figure of the same period on 2025.
Online stock assessment site Zacks said Harrow’s quarterly loss of $0.63 per share was about 48.2 percent more than its analysts’ consensus estimate of a loss of $0.43. This compares to a loss of $0.38 per share from Q1 2025.
Similarly, Harrow missed the Zacks consensus estimate for revenue by 12.17 percent.
Harrow CEO Mark Baum said said the company has now “fully deployed” its prescription drug trio of Vevye, Iheezo and Triesence.
“The demand for Harrow’s key products has never been stronger, and our visibility into our demand trajectory – across our portfolio – keeps us entirely on track to reach our forecasted financial goals for the year,” Baum said in the release.
“Across our key growth drivers (Vevye, Iheezo and Triesence), we are seeing robust prescriber adoption, expanding market share and durable momentum. With our expanded commercial organization now fully deployed, we remain highly confident in our ability to deliver on our 2026 revenue guidance of $350 million to $365 million.”
Harrow shares opened the year priced at $49.05 and have lost about 40.8 percent of value since.
{{description}}
Email notifications are only sent once a day, and only if there are new matching items.
Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:
